NO20042101L - N-Formylderivater av paroksetin - Google Patents
N-Formylderivater av paroksetinInfo
- Publication number
- NO20042101L NO20042101L NO20042101A NO20042101A NO20042101L NO 20042101 L NO20042101 L NO 20042101L NO 20042101 A NO20042101 A NO 20042101A NO 20042101 A NO20042101 A NO 20042101A NO 20042101 L NO20042101 L NO 20042101L
- Authority
- NO
- Norway
- Prior art keywords
- paroxetine
- compound
- formylparoxetine
- formula
- composition
- Prior art date
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 13
- 229960002296 paroxetine Drugs 0.000 title abstract 13
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- -1 paroxetine compound Chemical class 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000012360 testing method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33043001P | 2001-10-22 | 2001-10-22 | |
| PCT/NL2002/000654 WO2003044012A1 (en) | 2001-10-22 | 2002-10-15 | N-formyl derivatives of paroxetine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042101L true NO20042101L (no) | 2004-05-21 |
Family
ID=23289741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042101A NO20042101L (no) | 2001-10-22 | 2004-05-21 | N-Formylderivater av paroksetin |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6703408B2 (de) |
| EP (1) | EP1440067B1 (de) |
| AR (1) | AR036860A1 (de) |
| AT (1) | ATE285408T1 (de) |
| AU (1) | AU2002330771A1 (de) |
| CA (1) | CA2464327A1 (de) |
| DE (2) | DE60202381T2 (de) |
| DK (1) | DK1440067T3 (de) |
| ES (1) | ES2230516T3 (de) |
| HU (1) | HUP0401895A2 (de) |
| IL (1) | IL161521A0 (de) |
| NO (1) | NO20042101L (de) |
| NZ (1) | NZ532432A (de) |
| PT (1) | PT1440067E (de) |
| WO (1) | WO2003044012A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777554B2 (en) | 2001-02-05 | 2004-08-17 | Teva Pharmaceutical Industries Ltd. | Preparation of N-methylparoxetine and related intermediate compounds |
| EP1778183B1 (de) * | 2004-08-18 | 2018-06-27 | Synthon B.V. | Flüssige paroxetinzusammensetzungen |
| WO2007058998A2 (en) * | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
| CN109507349A (zh) * | 2017-09-15 | 2019-03-22 | 万全万特制药江苏有限公司 | 液相色谱法分离测定帕罗西汀中间体光学异构体的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| EP0223403B1 (de) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel |
| GB9325644D0 (en) * | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
| US5856493A (en) * | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
| JP3446468B2 (ja) | 1996-04-15 | 2003-09-16 | 旭硝子株式会社 | ピペリジンカルビノール類の製造方法 |
| EP0812829A1 (de) | 1996-06-14 | 1997-12-17 | Ontogen Corporation | Substituierte Imidazole als Modulatoren für Mehrfachresistenz gegen Medikamente |
| PL337513A1 (en) | 1997-05-29 | 2000-08-28 | Smithkline Beecham Corp | Novel method of obtaining pharmaceutically active compounds and their associated intermediate products |
| GB9810181D0 (en) * | 1998-05-13 | 1998-07-08 | Smithkline Beecham Plc | Novel formulations |
| WO2000026187A1 (en) | 1998-11-02 | 2000-05-11 | Synthon B.V. | Process for producing 4-arylpiperidine-3-carbinols and related compounds |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| GB9916392D0 (en) | 1999-07-13 | 1999-09-15 | Smithkline Beecham Plc | Novel process |
| IT1313702B1 (it) | 1999-08-02 | 2002-09-09 | Chemi Spa | Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine. |
| WO2002017921A2 (en) * | 2000-08-28 | 2002-03-07 | Synthon B.V. | Paroxetine compositions and processes for making the same |
| US6755653B2 (en) * | 2001-10-25 | 2004-06-29 | Cubic Defense Systems, Inc. | System and method for preventing cheating in a simulated combat exercise |
-
2002
- 2002-10-15 DK DK02768169T patent/DK1440067T3/da active
- 2002-10-15 WO PCT/NL2002/000654 patent/WO2003044012A1/en not_active Ceased
- 2002-10-15 AT AT02768169T patent/ATE285408T1/de not_active IP Right Cessation
- 2002-10-15 CA CA002464327A patent/CA2464327A1/en not_active Abandoned
- 2002-10-15 DE DE60202381T patent/DE60202381T2/de not_active Expired - Fee Related
- 2002-10-15 HU HU0401895A patent/HUP0401895A2/hu unknown
- 2002-10-15 DE DE20220955U patent/DE20220955U1/de not_active Expired - Lifetime
- 2002-10-15 NZ NZ532432A patent/NZ532432A/en unknown
- 2002-10-15 EP EP02768169A patent/EP1440067B1/de not_active Expired - Lifetime
- 2002-10-15 PT PT02768169T patent/PT1440067E/pt unknown
- 2002-10-15 IL IL16152102A patent/IL161521A0/xx unknown
- 2002-10-15 AU AU2002330771A patent/AU2002330771A1/en not_active Abandoned
- 2002-10-15 ES ES02768169T patent/ES2230516T3/es not_active Expired - Lifetime
- 2002-10-21 US US10/274,051 patent/US6703408B2/en not_active Expired - Fee Related
- 2002-10-21 AR ARP020103949A patent/AR036860A1/es not_active Application Discontinuation
-
2004
- 2004-01-20 US US10/759,437 patent/US20040147497A1/en not_active Abandoned
- 2004-01-20 US US10/759,436 patent/US20040266825A1/en not_active Abandoned
- 2004-05-21 NO NO20042101A patent/NO20042101L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL161521A0 (en) | 2004-09-27 |
| AU2002330771A1 (en) | 2003-06-10 |
| DE60202381T2 (de) | 2005-12-08 |
| HUP0401895A2 (hu) | 2004-12-28 |
| EP1440067B1 (de) | 2004-12-22 |
| US6703408B2 (en) | 2004-03-09 |
| DE20220955U1 (de) | 2004-09-02 |
| NZ532432A (en) | 2005-02-25 |
| AR036860A1 (es) | 2004-10-06 |
| WO2003044012A1 (en) | 2003-05-30 |
| PT1440067E (pt) | 2005-02-28 |
| CA2464327A1 (en) | 2003-05-30 |
| EP1440067A1 (de) | 2004-07-28 |
| US20040266825A1 (en) | 2004-12-30 |
| DE60202381D1 (de) | 2005-01-27 |
| US20040147497A1 (en) | 2004-07-29 |
| DK1440067T3 (da) | 2005-04-11 |
| ATE285408T1 (de) | 2005-01-15 |
| US20030125560A1 (en) | 2003-07-03 |
| ES2230516T3 (es) | 2005-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100773622B1 (ko) | 지프라시돈의 제어된 합성법 및 그의 조성물 | |
| Morley et al. | β-Amyloid precursor polypeptide in SAMP8 mice affects learning and memory | |
| Forsling et al. | The effect of 3, 4‐methylenedioxymethamphetamine (MDMA,? ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus | |
| CN105121437B (zh) | 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法 | |
| Scheuer et al. | Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain | |
| EP1721609A2 (de) | Pyridylpyrimidinderivate als effektive Verbindungen gegen Prioninfektionen und Prionerkrankungen | |
| JP2002539260A (ja) | アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法 | |
| Overø | Preliminary studies of the kinetics of citalopram in man | |
| US20110269703A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| AU655075B2 (en) | N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines | |
| WO2010055022A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| HUT70518A (en) | New indol derivatives, pharmaceutical compositions containing them and process for producing them | |
| Taguchi et al. | Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal | |
| KR20200061310A (ko) | 히스톤 탈아세틸화효소 6 억제제를 포함하는 약학적 조성물 | |
| JPWO2019009355A1 (ja) | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 | |
| NO20042101L (no) | N-Formylderivater av paroksetin | |
| CN109651321B (zh) | 一种芹菜素-o-烷基胺类化合物、制备方法和应用 | |
| JP2008538583A (ja) | アパシー症候群を治療するための方法 | |
| DE69618765T2 (de) | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein | |
| DK200300349U3 (da) | Fast farmaceutisk dosisform omfattende amlodipinmaleat | |
| JP2003507721A (ja) | 組成物中のオメプラゾールの異性体比のｆｔ−ラマン分光測定 | |
| JP2003507721A5 (de) | ||
| US20110251160A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| CZ298398A3 (cs) | Farmaceutický přípravek | |
| CN106831573A (zh) | (n‑1,2,3,4‑四氢异喹啉基)‑阿魏酰胺化合物、制备方法及其应用 |